4 citations
,
January 2023 in “Skin health and disease” This study shows that in a mouse model of Alopecia Areata, selective JAK1 inhibition facilitated hair regrowth and inflammation resolution while potentially offering a better safety profile compared to pan-JAK inhibition.
2 citations
,
November 2025 in “Journal of the American Academy of Dermatology” In this randomized, placebo-controlled trial, adults with severe chronic alopecia areata who received deuruxolitinib showed significant hair regrowth compared to placebo over 24 weeks, and the treatment was generally well-tolerated, though long-term effects remain unexamined.
September 2019 in “Journal of Investigative Dermatology” In this study, dose-response modeling predicted that once-daily abrocitinib doses of 100 mg and 200 mg may provide a clinically meaningful response in treating moderate-to-severe atopic dermatitis compared to placebo.
34 citations
,
June 2020 in “British journal of dermatology/British journal of dermatology, Supplement” In this study, researchers observed that follicular damage and stem cell loss in frontal fibrosing alopecia may be mediated by immune attacks at the bulge region, suggesting potential for JAK/STAT-targeting treatments to prevent progression.
September 2025 in “Chinese Journal of Chromatography” This study developed a method using ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MRM-IDA-EPI) for the rapid and sensitive detection of 13 JAK inhibitors in anti-alopecia cosmetics, showing excellent separation and accurate quantification with high recovery rates in tested matrices.